Replies to post #722025 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

suit,

You’re spreading baseless rumors as usual. LP is a shareholder too, and her position is about 130 million shares if I remember correctly, so nobody believes your nonsensical conspiracy theories 😶

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175121839

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175094676

[XMaster2023]

Theory, your theory has been distorted by your employer. NWBO will be successful with DCVax-L. Approval is near!

[dstock07734]

Is this your first investment in biotech? Biotech has certain requirement on your mindset. Especially now, the company is delivering revolutionary technology. Unless you want to go broke, you should stop your senseless BS and listen.

See how many trials on dendritic cells on clinicaltrials.gov. Over 500, but there is only one DC vaccine can do the following.

As the Company previously reported, proteomic studies have demonstrated that a single tumor lysate sample contained tens of thousands of different peptides and, out of this pool, the dendritic cells selected, processed and presented over 600 different peptides (tumor targets) to T cells. T cell studies (TCR sequencing and T cell clonal expansion assays) analyzing the breadth and strength of T cell response following DCVax-L treatment have found extensive responses, including clonal expansion of up to 800 T cell clones at month 4 and up to 1200 T cell clones at month 8 in the samples studied. Each T cell clone focuses on a particular and distinct target. In individuals not being treated with the vaccine, only 2 – 20 new T cells clones are seen between month 4 and month 8.

The results of these proteomic, T cell and other studies provide support for what the Company believes to be the mechanism of action of DCVax-L: i.e., mobilizing a broad spectrum and strong de novo T cell response that addresses the extensive heterogeneity of GBM and overcomes the immunosuppressive microenvironment around the tumor.

https://clinicaltrials.gov/search?titles=%22dendritic%20cell%22

As a matter of fact, I repeatedly mentioning about this ever since the ASCO presentation. NWBO mentioned about last December. John Hempton blocked me right away when I showed him the data. He was scared, was he not? I bet you are scared too. Before the submission of the application package, you were more or less dormant. Right after the package was filed, your agitation started spiking and you have been agitated ever since. You do know you are in a trap, do you not? So stop digging.

[learningcurve2020]

100%.

Imagine a CEO who takes 20 years to develop a single treatment in a single cancer knowing the likelihood of some other effective treatment taking the lead, and she has no backup plan for shareholders...Well, at least she had one or two for herself.


Now, as fate would have it, GBM still has no good treatments, but LP could not have known that. And, in just the last few years, as management was trying to get from data lock to submission, a whole new crop of intriguing therapies has arrived to compete.